Karyopharm Therapeutics (KPTI) Non-Current Deferred Tax Liability (2018)

Karyopharm Therapeutics (KPTI) reported Non-Current Deferred Tax Liability of $15.5 million for Q4 2018.

Karyopharm Therapeutics (KPTI) Non-Current Deferred Tax Liability (2018) Analysis & Trends

Karyopharm Therapeutics has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $15.5 million in Q4 2018.

For the quarter ending Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $15.5 million; the trailing twelve-month figure through Dec 2018 stood at $15.5 million (changed N/A YoY), and the FY2018 full-year result was $15.5 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q4 2018 stood at $15.5 million.
The five-year high for Non-Current Deferred Tax Liability was $15.5 million in Q4 2018, with the low at $15.5 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Karyopharm Therapeutics	95.31 Mn	31.56 Mn	32.74 Mn

Download Data

Date	Value
Dec 31, 2018	15.54 Mn
Dec 31, 2018	15.54 Mn